©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 16, 2022; 10(32): 11889-11897
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11889
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11889
Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature
Meng-Ye He, Fei-Fei Yan, Kai-Li Cen, Peng Shen, Department of Medical Oncology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China
Author contributions: He MY, Shen P designed the research study; He MY, Yan FF and Cen KL analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Meng-Ye He, MD, Doctor, Department of Medical oncology, First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. 1511051@zju.edu.cn
Received: June 23, 2022
Peer-review started: June 23, 2022
First decision: August 22, 2022
Revised: September 1, 2022
Accepted: October 17, 2022
Article in press: October 17, 2022
Published online: November 16, 2022
Processing time: 137 Days and 19.2 Hours
Peer-review started: June 23, 2022
First decision: August 22, 2022
Revised: September 1, 2022
Accepted: October 17, 2022
Article in press: October 17, 2022
Published online: November 16, 2022
Processing time: 137 Days and 19.2 Hours
Core Tip
Core Tip: The first-line standard treatment for advanced intrahepatic cholangiocarcinoma has been programmed cell death ligand 1 antibody combined with gemcitabine + cisplatin therapy, but the median overall survival time still could not break 1 year. However, this patient achieved clinical complete remission after second-line treatment with paclitaxel combined with programmed death 1 antibody and has survived for more than 32 mo. And we performed genetic testing of tissue specimens and found that this patient was without known predictive biomarkers related to immunotherapy efficacy but with BRCA1, KRAS and NTRK3 mutation, and whether there is a therapeutic efficacy correlation deserves further exploration.